- Idronoxil enhances anti-cancer effect of main cancer drug on primary brain cancers
- Idronoxil able to kill highly drug-resistant brain cancer cells
- Effect of idronoxil unaffected by expression of gene causing resistance to therapy
- Aim to be testing NOX66 in patients with brain cancer in 2018.
Sydney, 29 August 2017: Noxopharm is pleased to report that recent research findings represent major steps forward in its goal of using its frontline anti-cancer drug, NOX66, to treat primary cancers of the brain and bring the drug closer to the clinic.
For further information please download PDF attached:
Download this document
